💬 GLP-1 investors: Tired of only giants dominating the weight-loss space? Think small-cap biotechs can still deliver 10-bagger returns? Which under-the-radar name is on your watchlist?
While global drugmakers flood into the GLP-1 sector, and giants build deep moats with tens of billions in annual revenue, one small biotech company with a $4 billion market cap is quietly approaching its “moment of truth.”
$Viking Therapeutics(VKTX)$ has no approved products yet, but its core pipeline drug VK2735 is hitting a critical inflection point. The company plans to release clinical data for the drug as a maintenance dose in the third quarter of this year.
If the results are positive, this small-to-mid-sized biotech could see a short-term price surge and carve out meaningful market share from giants Novo Nordisk and Eli Lilly.
A Binary Gamble
Viking’s situation is widely known among investors as a “binary bet” — if VK2735 succeeds, the stock could skyrocket; if it fails, the price will likely crash back to baseline.
This sharp high-risk, high-reward profile defines the biotech stock’s core appeal.
The injectable version of VK2735 is already in Phase 3 trials, and a Phase 3 study for the oral formulation is scheduled to launch before year-end.
Even more notably, Viking is exploring the drug’s potential as a maintenance treatment — patients don’t have to restart therapy from scratch, but instead switch to VK2735 for long-term weight management after achieving significant weight loss.
If this strategy proves viable, it could drastically widen its addressable market.
Unlike many early-stage biotechs with distant catalysts, Viking’s catalysts are coming month by month.
Based on “exciting early data,” the company has launched studies evaluating VK2735 as a maintenance dose, covering monthly injectable formulations and daily/weekly oral options.
The results expected in Q3 will mark the first critical milestone validating this game-changing strategy.
Acquisition Appeal Before a $100B+ Pie
The GLP-1 market has explosive long-term prospects. Industry forecasts widely predict global annual sales of related drugs will hit $100 billion by around 2030, with the rise of oral formulations as a key growth driver.
Against this backdrop, Viking’s small size becomes a major advantage.
With a market cap of only about $4 billion, it stands in stark contrast to the trillion-dollar valuations of Novo and Lilly — making it a high-value, attractive acquisition target for large pharmaceutical companies.
Analysts believe if follow-up data for VK2735 remains consistently positive, Viking could receive a premium buyout offer. A bid at 3x current valuation is far from unrealistic.
The stock once traded near $100 per share; today, it hovers at only around $32.
Buy the Dip or Wait?
Since 2026, Viking’s stock has dropped 6%, and it’s down 24% from its 52-week high.
The company is not yet profitable, posting a $360 million net loss last year, with nearly all hopes riding on VK2735.
This is a classic “all-or-nothing” investment — any setback in clinical data could trigger extreme volatility.
For investors with strong risk tolerance, the current window could be a quiet setup before the dust settles.
In the crowded but still red-hot GLP-1 space, small-cap names with differentiation potential are rare.
Viking is using its “make-or-break moment” to secure a ticket to the massive weight-loss market.
No matter the outcome, this under-the-radar dark horse will face its “truth moment” this third quarter.
For SG users only, Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with unlimited trading on SG, HK, and US stocks, as well as ETFs.
🎉Cash Boost Account Now Supports 35,000+ Stocks & ETFs – Greater Flexibility Now
Find out more here.
Complete your first Cash Boost Account trade with a trade amount of ≥ SGD1000* to get SGD 688 stock vouchers*! The trade can be executed using any payment type available under the Cash Boost Account: Cash, CPF, SRS, or CDP.
Other helpful links:
Comments